European Patent Office

T 0401/16 (Bilayer pharmaceutical tablet / BOEHRINGER INGELHEIM) of 05.11.2020

European Case Law Identifier
ECLI:EP:BA:2020:T040116.20201105
Date of decision
5 November 2020
Case number
T 0401/16
Online on
25 January 2021
Petition for review of
-
Application number
10179142.4
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
Bilayer pharmaceutical tablet comprising telmisartan and a diuretic
Applicant name
Boehringer Ingelheim Pharma GmbH & Co. KG
Opponent name
reuteler & cie SA
Laboratorios Liconsa, S.A.
Generics [UK] Limited
LEK Pharmaceuticals d.d.
Board
3.3.07
Headnote
-
Relevant legal provisions
Rules of procedure of the Boards of Appeal Art 12(4) (2007)Rules of procedure of the Boards of Appeal Art 13(1) (2020)Rules of procedure of the Boards of Appeal Art 25(2) (2020)European Patent Convention Art 114(2) (2007)European Patent Convention Art 76(1) (2007)European Patent Convention Art 123(2) (2007)European Patent Convention Art 83 (2007)European Patent Convention Art 54 (2007)European Patent Convention Art 56 (2007)
Keywords
Late-filed evidence - admittance of documents filed in appeal proceedings
Amendments - extension beyond the content of the (earliest) application as filed (no)
Sufficiency of disclosure - (yes)
Public prior use - (no)
Novelty - (yes)
Inventive step - (yes)
Catchword
-
Cited cases
-
Citing cases
-

Order

For these reasons it is decided that:

The appeals are dismissed.